InvestorsHub Logo
Followers 4
Posts 1139
Boards Moderated 0
Alias Born 04/27/2006

Re: None

Friday, 12/02/2016 5:56:09 PM

Friday, December 02, 2016 5:56:09 PM

Post# of 9119
"THOUSAND OAKS, Calif., Dec. 2, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215, a biosimilar candidate to Avastin® (bevacizumab). The companies believe this submission is the first bevacizumab biosimilar application submitted to the EMA."

Roche should have continued the Enhanze platform development with Avastin.

Never argue with a fool, for after awhile, it becomes difficult to determine which is the fool.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News